ABL Acquires CDL Pharma to Develop CRO-related Services and Assays Manufacturing Capacity

Adds powerful capabilities for centralized biological analyses and molecular diagnostics assays manufacturing

LUXEMBOURG, July 11, 2018 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL – https://www.ablsa.com) announced today that it has signed a definitive agreement to acquire CDL Pharma (http://www.cdlpharma.com/), a company headquartered in France.  CDL Pharma provides comprehensive biological sample management solutions in clinical research, designed for pharmaceutical laboratories, CROs, biotechnology companies, and all participants in biomedical research.

CDL Pharma designs, produces and organizes the distribution of sampling kits from related-specific projects and provides international logistic support, as well as collection, processing and storage of biological samples at short, medium and long-term storage (-196°C, -80°C, -20°C, +4°C and room temperature). CDL Pharma also proposes data management services related to biological samples.

CDL Pharma is also specialized in the manufacturing of in-vitro diagnostic kits in the field of immunology, molecular biology and infectious diseases through the quality management standard ISO 9001:2015.

This acquisition is a natural evolution of ABL expertise which will help consolidating and developing its products and services portfolio around clinical data management (Nadis® platform technology) and manufacturing of molecular biology products including DNA/RNA sequencing for genotyping and drug resistance determination (DeepChek®) and quantification (UltraGene™) assays (viral load) for microbiology applications like HIV, HBV, HCV, CMV, Tuberculosis, HPV, 16s RNA…

"We are delighted to welcome CDL Pharma and are glad to extend ABL products and services to new areas including clinical research and in-vitro diagnostic kits manufacturing. This acquisition is an important asset for ABL to keep targeting ambitious milestones like completing its products portfolio with CE IVD assays" said Dr Chalom Sayada, CEO of ABL.

"We are committed to serving all the CDL Pharma clients with the same level of exigence and expertise and will provide new exciting products and services in a near future. Simultaneously we will continue to grow our multi-skilled team of specialists including data and project managers and laboratory experts" added Dr Sayada.

Financial details of the agreement were not disclosed. 

About ABL

Advanced Biological Laboratories (ABL), S.A., is a Diagnostic and Medical Software company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL's products offer to infectious disease clinicians, virology and microbiology laboratories optimal and efficient solutions (assays and software systems related to HIV, HCV, HBV, HPV, CMV, tuberculosis…) for sequencing (DeepChek®) clinical genotyping, viral load (UltraGene™) and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC® and the DPM used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products like ViroScore® Suite and DeepChek® are for research use only in the United States, and the data processing module is an FDA registered class I medical device. These are currently available for Research Use Only.

About CDL Pharma

CDL Pharma is a CRO (Contract Research Organization) that offers comprehensive biological sample management solutions in clinical research. CDL Pharma, created in 2005, is a simplified joint-stock company with a capital of € 37.000. which relies on a strong experience in centralized biology acquired before the creation of the company within the Alphabio Laboratory. CDL Pharma is certified ISO 9001 V2015 for all its activities with quality system allowing compliance with Internationally recognized standards ( GCP, GCLP…).

Media Contact: Chalom Sayada, Advanced Biological Laboratories, +352263896761, chalom@ablsa.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

SOURCE Advanced Biological Laboratories



Related Links
2018

Categories

Money, Health & Living


Tags

Biotechnology, Health Care & Hospitals, Acquisitions, Mergers and Takeovers


Need Help